Search Results - "Chittenden, Sarah J"

Excretion and whole-body retention of radium-223 dichloride administered for the treatment of bone metastases from castration resistant prostate cancer by Pratt, Brenda E, Hindorf, Cecilia, Chittenden, Sarah J, Parker, Christopher C, Flux, Glenn D

“…OBJECTIVEThe aim of the study was to determine the fraction of administered activity that was excreted and retained by a small cohort of patients who each…”
Get full text

A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer by Flux, Glenn D., Haq, Masud, Chittenden, Sarah J., Buckley, Susan, Hindorf, Cecilia, Newbold, Kate, Harmer, Clive L.

“…Purpose The aim of this study was to determine the range of absorbed doses delivered to thyroid remnants, blood, and red marrow from fixed administrations of…”
Get full text

Phase I/II trials of 186Re-HEDP in metastatic castration-resistant prostate cancer: post-hoc analysis of the impact of administered activity and dosimetry on survival by Denis-Bacelar, Ana M., Chittenden, Sarah J., Dearnaley, David P., Divoli, Antigoni, O’Sullivan, Joe M., McCready, V. Ralph, Johnson, Bernadette, Du, Yong, Flux, Glenn D.

“…Purpose To investigate the role of patient-specific dosimetry as a predictive marker of survival and as a potential tool for individualised molecular…”
Get full text

Compartmental Model for 223Ra-Dichloride in Patients With Metastatic Bone Disease From Castration-Resistant Prostate Cancer by Taprogge, Jan, Murray, Iain, Gear, Jonathan, Chittenden, Sarah J., Parker, Christopher C., Flux, Glenn D.

“…223Ra-Dichloride is used for treatment of patients with metastatic bone disease from castration-resistant prostate cancer. The uptake and mechanism of action…”
Get full text

Bone lesion absorbed dose profiles in patients with metastatic prostate cancer treated with molecular radiotherapy by Denis-Bacelar, Ana M, Chittenden, Sarah J, McCready, V Ralph, Divoli, Antigoni, Dearnaley, David P, O'Sullivan, Joe M, Johnson, Bernadette, Flux, Glenn D

“…The aim of this study was to calculate the range of absorbed doses that could potentially be delivered by a variety of radiopharmaceuticals and typical fixed…”
Get full text

A radiobiological model of metastatic burden reduction for molecular radiotherapy: application to patients with bone metastases by Denis-Bacelar, Ana M, Chittenden, Sarah J, Murray, Iain, Divoli, Antigoni, Ralph McCready, V, Dearnaley, David P, O'Sullivan, Joe M, Johnson, Bernadette, Flux, Glenn D

“…Skeletal tumour burden is a biomarker of prognosis and survival in cancer patients. This study proposes a novel method based on the linear quadratic model to…”
Get more information

The potential of 223Ra and 18F-fluoride imaging to predict bone lesion response to treatment with 223Ra-dichloride in castration-resistant prostate cancer by Murray, Iain, Chittenden, Sarah J., Denis-Bacelar, Ana M., Hindorf, Cecilia, Parker, Christopher C., Chua, Sue, Flux, Glenn D.

“…Purpose The aims of this study were to calculate bone lesion absorbed doses resulting from a weight-based administration of 223 Ra-dichloride, to assess the…”
Get full text

Reply to ‘Single high dose versus repeated bone-targeted radionuclide therapy’ by Denis-Bacelar, Ana M., Chittenden, Sarah J., Dearnaley, David P., Divoli, Antigoni, O’Sullivan, Joe M., McCready, V. Ralph, Johnson, Bernadette, Du, Yong, Flux, Glenn D.

Get full text

InfuShield: a shielded enclosure for administering therapeutic radioisotope treatments using standard syringe pumps by Rushforth, Dominic P, Pratt, Brenda E, Chittenden, Sarah J, Murray, Iain S, Causer, Louise, Grey, Matthew J, Gear, Jonathan I, Du, Yong, Flux, Glenn D

“…The administration of radionuclide therapies presents significant radiation protection challenges. The aim of this work was to develop a delivery system for…”
Get full text

Reply to: Can an undetectable value of TG and a negative neck ultrasound study be considered reliable methods to assess the completeness of thyroid ablation? by Flux, Glenn D., Haq, Masud, Chittenden, Sarah J., Buckley, Susan, Hindorf, Cecilia, Newbold, Kate, Harmer, Clive L.

Get full text

Whole-Body Dosimetry for Individualized Treatment Planning of 131I-MIBG Radionuclide Therapy for Neuroblastoma by Buckley, Susan E, Chittenden, Sarah J, Saran, Frank H, Meller, Simon T, Flux, Glenn D

“…The aims of this study were to examine the relationship between whole-body absorbed dose and hematologic toxicity and to assess the most accurate method of…”
Get full text

Optimization of equipment and methodology for whole body activity retention measurements in children undergoing targeted radionuclide therapy by Chittenden, Sarah J, Pratt, Brenda E, Pomeroy, Kay, Black, Peter, Long, Clive, Smith, Nicholas, Buckley, Susan E, Saran, Frank H, Flux, Glenn D

“…Accurate measurements of whole-body activity retention of patients during radionuclide therapy are essential for two reasons: First, they enable the correct…”
Get more information

A Phase 1, Open-Label Study of the Biodistribution, Pharmacokinetics, and Dosimetry of Ra-223-Dichloride in Patients with Hormone-Refractory Prostate Cancer and Skeletal Metastases by Chittenden, Sarah J., Hindorf, Cecilia, Parker, Christopher C., Lewington, Valerie J., Pratt, Brenda E., Johnson, Bernadette, Flux, Glenn D.

“…The aim of this single-site, open-label clinical trial was to determine the biodistribution, pharmacokinetics, absorbed doses, and safety from 2 sequential…”
Get full text

Absorbed dose ratios for repeated therapy of neuroblastoma with I-131 mIBG by Flux, Glenn D, Guy, Matt J, Papavasileiou, Periklis, South, Chris, Chittenden, Sarah J, Flower, Maggie A, Meller, Simon T

“…Patients undergoing targeted radionuclide therapy (TRT) may receive a series of two or more treatment administrations at varying intervals. However, the level…”
Get more information

The potential of ^sup 223^Ra and ^sup 18^F-fluoride imaging to predict bone lesion response to treatment with ^sup 223^Ra-dichloride in castration-resistant prostate cancer by Murray, Iain, Chittenden, Sarah J, Denis-bacelar, Ana M, Hindorf, Cecilia, Parker, Christopher C, Chua, Sue, Flux, Glenn D

“…Purpose The aims of this study were to calculate bone lesion absorbed doses resulting from a weight-based administration of 223Ra-dichloride, to assess the…”
Get full text

A Phase 1, Open-Label Study of the Biodistribution, Pharmacokinetics, and Dosimetry of 223 Ra-Dichloride in Patients with Hormone-Refractory Prostate Cancer and Skeletal Metastases by Chittenden, Sarah J., Hindorf, Cecilia, Parker, Christopher C., Lewington, Valerie J., Pratt, Brenda E., Johnson, Bernadette, Flux, Glenn D.

Get full text

A Phase 1, Open-Label Study of the Biodistribution, Pharmacokinetics, and Dosimetry of sigma up 223 nu a-Dichloride in Patients with Hormone-Refractory Prostate Cancer and Skeletal Metastases by Chittenden, Sarah J, Hindorf, Cecilia, Parker, Christopher C, Lewington, Valerie J, Pratt, Brenda E, Johnson, Bernadette, Flux, Glenn D

“…The aim of this single-site, open-label clinical trial was to determine the biodistribution, pharmacokinetics, absorbed doses, and safety from 2 sequential…”
Get full text

A Phase 1, Open-Label Study of the Biodistribution, Pharmacokinetics, and Dosimetry of ^sup 223^Ra-Dichloride in Patients with Hormone-Refractory Prostate Cancer and Skeletal Metastases by Chittenden, Sarah J, Hindorf, Cecilia, Parker, Christopher C, Lewington, Valerie J, Pratt, Brenda E, Johnson, Bernadette, Flux, Glenn D

“…The aim of this single-site, open-label clinical trial was to determine the biodistribution, pharmacokinetics, absorbed doses, and safety from 2 sequential…”
Get full text

Three-Dimensional Dosimetry for Intralesional Radionuclide Therapy Using Mathematical Modeling and Multimodality Imaging by Flux, Glenn D, Webb, Steve, Ott, Robert J, Chittenden, Sarah J, Thomas, Robert

“…A method of dosimetry is described that quantifies the three-dimensional absorbed-dose distribution resulting from an intralesional administration of a…”
Get full text

Phase I/II trials of ^sup 186^Re-HEDP in metastatic castration-resistant prostate cancer: post-hoc analysis of the impact of administered activity and dosimetry on survival by Denis-bacelar, Ana M, Chittenden, Sarah J, Dearnaley, David P, Divoli, Antigoni, O'sullivan, Joe M, Mccready, V Ralph, Johnson, Bernadette, Du, Yong, Flux, Glenn D

“…Purpose To investigate the role of patient-specific dosimetry as a predictive marker of survival and as a potential tool for individualized molecular…”
Get full text